Industry Problem
"Research use only. Not for human consumption." But also — buy now.
A parallel gray market for GLP-1 peptides operates outside the licensed provider framework — with serious implications for safety, quality, and legality.
The 'research chemical' peptide market exploits a regulatory gap: selling compounds for 'research use only' avoids the prescription requirement, but the products are clearly marketed to people who intend to self-administer them. This creates real risks — from inconsistent dosing to unverified sourcing to zero clinical oversight.
No quality control
Research-use peptides sold outside the pharmacy system are not subject to the same sterility, potency, or purity standards as compounded medications from licensed pharmacies. They are not sourced from FDA-registered manufacturers, are not accompanied by a Certificate of Analysis, and are often research-grade — not pharmaceutical-grade. Dosing is frequently inconsistent.
No provider oversight
Self-administering a GLP-1 agonist without a provider reviewing your health history, medications, and contraindications is clinically unsafe and can lead to serious adverse events.
Legal gray zone
Purchasing prescription-equivalent compounds under the 'research use' label may violate federal and state laws depending on jurisdiction and intended use.
No recourse
If you have a side effect or a dosing issue with a gray-market peptide, you have no clinical relationship, no provider to contact, and no accountability from the seller.
The NoBsRx Answer
Pharmaceutical-grade. Licensed. Verified.
NoBsRx does not source, sell, or facilitate access to research-use-only peptides. All treatment pathways involve licensed provider review and fulfillment through state-licensed 503A compounding pharmacies. Those pharmacies source their active pharmaceutical ingredients exclusively from FDA-registered manufacturers — pharmaceutical-grade, not research-grade — and every API is accompanied by a Certificate of Analysis verifying identity, quality, and compliance.